Australia markets closed
  • ALL ORDS

    7,624.30
    +23.80 (+0.31%)
     
  • ASX 200

    7,368.90
    +9.90 (+0.13%)
     
  • AUD/USD

    0.7487
    -0.0064 (-0.85%)
     
  • OIL

    71.50
    +0.46 (+0.65%)
     
  • GOLD

    1,763.90
    -10.90 (-0.61%)
     
  • BTC-AUD

    47,579.49
    -2,988.60 (-5.91%)
     
  • CMC Crypto 200

    884.52
    -55.43 (-5.90%)
     
  • AUD/EUR

    0.6308
    -0.0028 (-0.44%)
     
  • AUD/NZD

    1.0787
    +0.0009 (+0.09%)
     
  • NZX 50

    12,551.93
    +10.73 (+0.09%)
     
  • NASDAQ

    14,049.58
    -114.22 (-0.81%)
     
  • FTSE

    7,017.47
    -135.96 (-1.90%)
     
  • Dow Jones

    33,290.08
    -533.37 (-1.58%)
     
  • DAX

    15,448.04
    -279.63 (-1.78%)
     
  • Hang Seng

    28,801.27
    +242.68 (+0.85%)
     
  • NIKKEI 225

    28,964.08
    -54.25 (-0.19%)
     

Global Nonalcoholic Fatty Liver Disease Markets, Epidemiology and Patient Flow Report 2020-2035 - ResearchAndMarkets.com

·2-min read

The "Global Nonalcoholic Fatty Liver Disease Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.

Global Nonalcoholic Fatty Liver Disease Epidemiology and Patient Flow Analysis - 2021, provides Nonalcoholic Fatty Liver Disease epidemiology, demographics, and patient flow. The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.

The research provides population data to characterize Nonalcoholic Fatty Liver Disease patients, history of the disease at the population level (Nonalcoholic Fatty Liver Disease prevalence, Nonalcoholic Fatty Liver Disease incidence) and at the clinical level (from diagnosis to treated patients). It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.

Research scope:

  • Nonalcoholic Fatty Liver Disease patient flow: Nonalcoholic Fatty Liver Disease prevalence, diagnosed, and drug-treated patients

  • Countries: US, Germany, France, Italy, Spain, UK, Japan, G7 Countries

  • Demographics: Nonalcoholic Fatty Liver Disease patients by age group, gender

  • Forecast: Nonalcoholic Fatty Liver Disease epidemiology forecast to 2035

The data from this research will help executives:

  • Establish basis for Nonalcoholic Fatty Liver Disease market sizing, assessing market potential, and developing drug forecast models

  • Identify Nonalcoholic Fatty Liver Disease patients segments through age groups, gender, and disease sub-types

  • Develop Nonalcoholic Fatty Liver Disease population-based health management frameworks

  • Evaluate Nonalcoholic Fatty Liver Disease market opportunities, identify target patient population

  • Align marketing decisions with the Nonalcoholic Fatty Liver Disease target population

  • Communicate leadership and health authorities about your Nonalcoholic Fatty Liver Disease target patient population

Key Topics Covered:

1. Research Methodology

2. Nonalcoholic Fatty Liver Disease Patients Definition

3. US Nonalcoholic Fatty Liver Disease Epidemiology and Patient Flow

4. Germany Nonalcoholic Fatty Liver Disease Epidemiology and Patient Flow

5. France Nonalcoholic Fatty Liver Disease Epidemiology and Patient Flow

6. Italy Nonalcoholic Fatty Liver Disease Epidemiology and Patient Flow

7. Spain Nonalcoholic Fatty Liver Disease Epidemiology and Patient Flow

8. UK Nonalcoholic Fatty Liver Disease Epidemiology and Patient Flow

9. Europe Nonalcoholic Fatty Liver Disease Epidemiology and Patient Flow

10. Japan Nonalcoholic Fatty Liver Disease Epidemiology and Patient Flow

11. Global Nonalcoholic Fatty Liver Disease Epidemiology and Patient Flow

For more information about this report visit https://www.researchandmarkets.com/r/euv4ha

View source version on businesswire.com: https://www.businesswire.com/news/home/20210512005852/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting